Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney

Yuhki Koga, Akinobu Matsuzaki, Aiko Suminoe, Miho Hatano, Yusuke Saito, Yoshiaki Kinoshita, Tatsuro Tajiri, Tomoaki Taguchi, Kenichi Kohashi, Yoshinao Oda, Masazumi Tsuneyoshi, Toshiro Hara

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A 5-month-old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24-month-old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by highdose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT). Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication. Consolidation with SCT should be further studies for selected patients with high-risk MRTK.

Original languageEnglish
Pages (from-to)888-890
Number of pages3
JournalPediatric Blood and Cancer
Volume52
Issue number7
DOIs
Publication statusPublished - Jul 1 2009

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney'. Together they form a unique fingerprint.

  • Cite this